Trial Profile
A Randomized, Open-Label Study of Oral CEP-701 [lestaurtinib] Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Oct 2021
Price :
$35
*
At a glance
- Drugs Lestaurtinib (Primary) ; Cytarabine; Etoposide; Mitoxantrone
- Indications Acute myeloid leukaemia
- Focus Registrational; Therapeutic Use
- Sponsors Cephalon
- 04 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 May 2010 Actual end date (Jan 2010) added as reported by ClinicalTrials.gov.